Literature DB >> 31155639

Impacts of the MHC class I-like XNC10 and innate-like T cells on tumor tolerance and rejection in the amphibian Xenopus.

Maureen Banach1, Eva-Stina Edholm2, Xavier Gonzalez1, Abdellatif Benraiss3, Jacques Robert1.   

Abstract

The conditions that lead to antitumor or protumor functions of natural killer T (NKT) cells against mammalian tumors are only partially understood. Therefore, insights into the evolutionary conservation of NKT and their analogs-innate-like T (iT) cells-may reveal factors that contribute to tumor eradication. As such, we investigated the amphibian Xenopus laevis iT cells and interacting MHC class I-like (XNC or mhc1b.L) genes against ff-2 thymic lymphoid tumors. Upon ff-2 intraperitoneal transplantation into syngeneic tadpoles, two iT cell subsets iVα6 and iVα22, characterized by an invariant T-cell receptor α chain rearrangement (Vα6-Jα1.43 and Vα22-Jα1.32 respectively), were recruited to the peritoneum, concomitant with a decreased level of these transcripts in the spleen and thymus. To address the hypothesize that different iT cell subsets have distinct, possibly opposing, roles upon ff-2 tumor challenge, we determined whether ff-2 tumor growth could be manipulated by impairing Vα6 iT cells or by deleting their restricting element, the XNC gene, XNC10 (mhc1b10.1.L), on ff-2 tumors. Accordingly, the in vivo depletion of Vα6 iT cells using XNC10-tetramers enhanced tumor growth, indicating Vα6 iT cell-mediated antitumor activities. However, XNC10-deficient transgenic tadpoles that also lack Vα6 iT cells were resistant to ff-2 tumors, uncovering a potential new function of XNC10 besides Vα6 iT cell development. Furthermore, the CRISPR/Cas9-mediated knockout of XNC10 in ff-2 tumors broke the immune tolerance. Together, our findings demonstrate the relevance of XNC10/iT cell axis in controlling Xenopus tumor tolerance or rejection.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31155639      PMCID: PMC6642367          DOI: 10.1093/carcin/bgz100

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  49 in total

1.  Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model.

Authors:  Barry J Kappel; Javier Pinilla-Ibarz; Adam A Kochman; Jeffrey M Eng; Vanessa M Hubbard; Ingrid Leiner; Eric G Pamer; Glen Heller; Marcel R M van den Brink; David A Scheinberg
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

Review 2.  CD1d ligands: the good, the bad, and the ugly.

Authors:  Randy R Brutkiewicz
Journal:  J Immunol       Date:  2006-07-15       Impact factor: 5.422

3.  Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent.

Authors:  Suzanne Ostrand-Rosenberg; Virginia K Clements; Masaki Terabe; Jong Myun Park; Jay A Berzofsky; Samudra K Dissanayake
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

4.  CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta.

Authors:  Masaki Terabe; Chand Khanna; Seuli Bose; Fraia Melchionda; Arnulfo Mendoza; Crystal L Mackall; Lee J Helman; Jay A Berzofsky
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

5.  Involvement of nonclassical MHC class Ib molecules in heat shock protein-mediated anti-tumor responses.

Authors:  Ana Goyos; Sergey Guselnikov; Asiya S Chida; Lynn F Sniderhan; Sanjay B Maggirwar; Hristina Nedelkovska; Jacques Robert
Journal:  Eur J Immunol       Date:  2007-06       Impact factor: 5.532

6.  Ancestral organization of the MHC revealed in the amphibian Xenopus.

Authors:  Yuko Ohta; Wilfried Goetz; M Zulfiquer Hossain; Masaru Nonaka; Martin F Flajnik
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

7.  Systemic NKT cell deficiency in NOD mice is not detected in peripheral blood: implications for human studies.

Authors:  Stuart P Berzins; Kon Kyparissoudis; Daniel G Pellicci; Kristen J Hammond; Stephane Sidobre; Alan Baxter; Mark J Smyth; Mitchell Kronenberg; Dale I Godfrey
Journal:  Immunol Cell Biol       Date:  2004-06       Impact factor: 5.126

8.  Differential antitumor immunity mediated by NKT cell subsets in vivo.

Authors:  Nadine Y Crowe; Jonathan M Coquet; Stuart P Berzins; Konstantinos Kyparissoudis; Rachael Keating; Daniel G Pellicci; Yoshihiro Hayakawa; Dale I Godfrey; Mark J Smyth
Journal:  J Exp Med       Date:  2005-11-07       Impact factor: 14.307

9.  A natural killer T (NKT) cell developmental pathway iInvolving a thymus-dependent NK1.1(-)CD4(+) CD1d-dependent precursor stage.

Authors:  Daniel G Pellicci; Kirsten J L Hammond; Adam P Uldrich; Alan G Baxter; Mark J Smyth; Dale I Godfrey
Journal:  J Exp Med       Date:  2002-04-01       Impact factor: 14.307

10.  Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function.

Authors:  Daniel B Stetson; Markus Mohrs; R Lee Reinhardt; Jody L Baron; Zhi-En Wang; Laurent Gapin; Mitchell Kronenberg; Richard M Locksley
Journal:  J Exp Med       Date:  2003-10-06       Impact factor: 14.307

View more
  1 in total

Review 1.  γδ T, NKT, and MAIT Cells During Evolution: Redundancy or Specialized Functions?

Authors:  Christelle Harly; Jacques Robert; Francois Legoux; Olivier Lantz
Journal:  J Immunol       Date:  2022-07-15       Impact factor: 5.426

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.